BioNTech (NASDAQ:BNTX) Given Buy Rating at Canaccord Genuity Group

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating restated by stock analysts at Canaccord Genuity Group in a research note issued to investors on Thursday,Benzinga reports. They presently have a $171.00 price target on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 51.60% from the stock’s previous close.

A number of other brokerages have also issued reports on BNTX. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. UBS Group increased their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. lowered their price target on BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a report on Monday, November 4th. Finally, Bank of America raised their price objective on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $137.54.

BioNTech Stock Up 1.2 %

BNTX stock traded up $1.32 during trading on Thursday, reaching $112.80. The stock had a trading volume of 302,820 shares, compared to its average volume of 787,372. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average price of $113.08 and a 200 day moving average price of $97.05. The company has a market capitalization of $27.04 billion, a P/E ratio of -53.71 and a beta of 0.26. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the previous year, the firm posted $0.73 earnings per share. The company’s revenue was up 38.9% compared to the same quarter last year. On average, equities analysts anticipate that BioNTech will post -3.47 earnings per share for the current year.

Institutional Trading of BioNTech

A number of institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC increased its stake in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares during the period. Covestor Ltd increased its position in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of BioNTech by 2.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock valued at $904,000 after buying an additional 223 shares during the period. EverSource Wealth Advisors LLC boosted its stake in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares in the last quarter. Finally, Capital International Sarl grew its holdings in BioNTech by 1.3% during the first quarter. Capital International Sarl now owns 24,058 shares of the company’s stock worth $2,219,000 after acquiring an additional 310 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.